Metabolic Diabetes

Integrium’s Metabolic Clinical Trial Experience

Diabetes

Previous

Overall Metabolic Experience
Study Phase Indication Product Type # Sites # Patients Location Services
IIb Type 1 Diabetes Drug 15 167 US Full Scope
I Type 1 Diabetes Drug 1 24 US Full Scope
IIa Type 2 Diabetes Drug 2 30 US Full Scope
I / II Type 2 Diabetes Drug 2 37 US DM, Biostatistics, PM
II Type 2 Diabetes Drug 1 10 US Full Scope
II Diabetes Continuous Insulin Delivery Device 10 60 US Full Scope
II Type 2 Diabetes, Hypertension Drug 10 72 US PM, Monitoring
II Type 2 Diabetes Drug 12 75 US Full Scope
II Type 2 Diabetes Drug 12 82 US Full Scope
II Diabetes Drug 13 86 US PM, Monitoring, Medical
II Type 2 Diabetes Drug 22 150 US Full Scope
II Insulin Dependent Diabetes Drug 30 300 US, Europe Full Scope
II Insulin Dependent Diabetes Drug 32 300 US Full Scope
II Type 2 Diabetes Drug 33 194 US Full Scope
II Type 2 Diaebetes Nephropathy Drug 40 170 US DM, PM, Medical, Monitoring
IIa Type 2 Diabetes Drug 8 52 US Full Scope
IIa Type 2 Diabetes Drug 14 110 US Medical, PM, Monitoring
IIb Type 2 Diabetes Drug 20 191 US, Europe Full Scope
IIb Type 2 Diabetes Drug 24 180 US Full Scope
III Diabetes Drug 29 222 S. Africa Medical, PM, Monitoring
III Type 2 Diabetes Drug 150 1000 S. Africa, India, Europe PM, Monitoring, Medical
IV Type 2 Diabetes Drug 2 34 US Full Scope
IV Type 2 Diabetes Drug 5 55 US Full Scope
IV Type 2 Diabetes, Hypertension Drug 25 250 US Full Scope
IV Diabetes Drug 45 350 US Full Scope
IV Type 2 Diabetes Drug 132 1009 US, Canada PM, Monitoring, Medical
IV Type 2 Diabetes Drug 145 900 US, S. Africa PM, Monitoring, Medical, DM

Previous